Shattuck Labs, Inc.
NASDAQ:STTKBiotechnology
+$0.11 today
- Market cap
- $467.46M
- Beta
- 1.09
- P/E (TTM)
- -10.9
- EPS (TTM)
- -$0.44
Volume 0.79M
Average 0.69M
STTK EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Shattuck Labs, Inc.NASDAQ: STTK
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$13.88M, compared with -$12.77M a year earlier. Trailing-twelve-month EBITDA was -$46.23M.
Context
- EBITDA amounted to 4512.1% of revenue in FY2025, up 3260.9 pp from a year earlier.
- EBITDA grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of -$30.56M (+32.3%) for the fiscal year ending Dec 2026, a slowdown from the +37.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$13.88M-18.7% QoQ
- Last fiscal yearDec 2025
- -$45.12M+37.0% YoY
- LTMMar 2026
- -$46.23M+30.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -8.7% | — | — |
| 1 year | +37.0% | +32.3% | -4.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (45.12M) USD
- Year-over-year change
- +37.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (45.12M) | +37.0% |
| FY2024 | 2024-12-31 | (71.58M) | +14.0% |
| FY2023 | 2023-12-31 | (83.26M) | +15.8% |
| FY2022 | 2022-12-31 | (98.87M) | -126.8% |
| FY2021 | 2021-12-31 | (43.59M) | — |
EBITDA vs competitors
How STTK compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +30.8% is the 3rd highest of 10, against a peer median of -19.7%.
- EBITDA amounts to 4623.1% of revenue for STTK, versus a peer median of 48.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $44.91M USD | -17.8% | +34.6% | 19.8% | |
| LTM Mar 2026 | -$18.86M USD | -19.7% | — | — | |
| LTM Mar 2026 | -$27.92M USD | +15.6% | — | — | |
NBPNovaBridge Biosciences | LTM Sep 2025 | -CN¥33.25M CNY | +92.9% | — | — |
| LTM Sep 2026 | -$35.76M USD | -89.6% | — | — | |
| LTM Mar 2026 | -$38.09M USD | -800.9% | — | — | |
| LTM Mar 2026 | -$46.23M USD | +30.8% | — | 4623.1% | |
| LTM Mar 2026 | -$158.86M USD | -1227.0% | — | 1336.8% | |
| LTM Sep 2026 | -$185.11M USD | +47.9% | — | 48.8% | |
| LTM Jun 2026 | -$195.4M USD | -639.8% | — | — | |
| Peer median (excluding STTK) | — | -19.7% | +34.6% | 48.8% | |
Competitors are the stored peer set for STTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 30.02M | 652K | 1.66M | 5.72M | 1M |
| Cost of Revenue | 1.38M | 82.2M | 4.04M | 4.89M | 0 |
| Gross Profit | 28.64M | (81.55M) | (2.39M) | 827K | 1M |
| Gross Margin | 95.4% | -12507.2% | -143.9% | 14.5% | 100.0% |
| Research & Development | 56.56M | 82.9M | 74.31M | 67.21M | 35.27M |
| Selling, General & Admin | 18.72M | 19.68M | 19.3M | 19.08M | 17.24M |
| Operating Expenses | 73.91M | 21.78M | 89.57M | 81.39M | 52.51M |
| Depreciation & Amortization | 1.38M | 3.07M | 4.04M | 3.83M | 3.69M |
| EBITDA | (43.59M) | (98.87M) | (83.26M) | (71.58M) | (45.12M) |
| EBITDA Margin | -145.2% | -15164.4% | -5024.5% | -1251.2% | -4512.1% |
| Operating Income | (45.27M) | (103.33M) | (91.96M) | (80.57M) | (51.51M) |
| Operating Margin | -150.8% | -15848.0% | -5549.6% | -1408.3% | -5150.8% |
| Interest Income | 625K | 1.59M | 4.67M | 5.17M | 2.7M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 295K | 1.38M | 4.66M | 5.16M | 2.7M |
| Income Before Tax | (44.97M) | (101.95M) | (87.3M) | (75.41M) | (48.81M) |
| Pre-Tax Margin | -149.8% | -15635.7% | -5268.4% | -1318.1% | -4880.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (44.97M) | (101.95M) | (87.3M) | (75.41M) | (48.81M) |
| Net Margin | -149.8% | -15635.7% | -5268.4% | -1318.1% | -4880.9% |
| EPS (Basic) | (1.07) | (2.41) | (2.05) | (1.49) | (0.70) |
| EPS (Diluted) | (1.07) | (2.41) | (2.05) | (1.49) | (0.70) |
| Weighted Avg Shares | 42.03M | 42.38M | 42.6M | 50.76M | 69.58M |
| Weighted Avg Shares (Diluted) | 42.03M | 42.38M | 42.6M | 50.76M | 69.58M |
Shattuck Labs, Inc.
NASDAQ:STTK
Intrinsic Alpha fair value
Locked
Current Price
$4.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.